Co-Diagnostics announces 1-for-30 reverse stock split

Core Viewpoint - Co-Diagnostics (CODX) has announced a reverse stock split at a ratio of 1-for-30 shares to comply with Nasdaq's minimum bid price requirement [1] Group 1: Reverse Stock Split Details - The reverse stock split will take effect at 12:01 a.m. ET on January 2, 2026 [1] - Co-Dx's common stock will continue to trade on The Nasdaq Capital Market under the symbol "CODX" and will begin trading on a split-adjusted basis on the same date [1] - The new CUSIP number for Co-Dx's common stock after the reverse stock split will be 189763 204 [1] Group 2: Compliance and Listing - The purpose of the reverse stock split is to enable Co-Diagnostics to regain compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market [1]